PT-141 — reference
Melanocortin agonist. FDA-approved (Vyleesi) for acquired, generalized HSDD in premenopausal women.
Regulatory status
FDA-Approved (labeled use). FDA-approved for its labeled indication and population only. Off-label use (incl. in men) is not FDA-approved; community-reported doses for that use are often lower (~0.5–1 mg).
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~2.7 hours. FDA label (Vyleesi/bremelanotide).
This figure is tagged FDA label in our evidence system. This figure appears in an approved product's prescribing information, which is the strongest tier in our system — a regulator-reviewed number for a specific approved product. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is PT-141 FDA-approved?
What is the half-life of PT-141?
How reliable is that half-life figure?
What cautions are associated with PT-141?
Does Peptide Plug publish dosing for PT-141?
Does Peptide Plug sell PT-141?
Related tools
Free, no account required.
The public research page intentionally does not publish dosing. Pro subscribers can open the separate Protocol Library for structured indication, frequency, duration, notes, and review-first Cycle Builder import when a matching reference is available.
View Protocol Reference